A detailed history of Met Life Investment Management, LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 51,700 shares of MYGN stock, worth $791,010. This represents 0.01% of its overall portfolio holdings.

Number of Shares
51,700
Previous 51,700 -0.0%
Holding current value
$791,010
Previous $1.26 Million 11.95%
% of portfolio
0.01%
Previous 0.01%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$17.98 - $25.47 $138,320 - $195,940
7,693 Added 17.48%
51,700 $1.26 Million
Q1 2024

May 14, 2024

BUY
$17.59 - $23.59 $774,083 - $1.04 Million
44,007 New
44,007 $938,000
Q2 2023

Apr 29, 2024

BUY
$17.56 - $23.76 $749,267 - $1.01 Million
42,669 New
42,669 $989,000
Q1 2023

May 09, 2024

BUY
$15.26 - $23.75 $651,128 - $1.01 Million
42,669 New
42,669 $991 Million
Q1 2022

May 10, 2024

BUY
$22.67 - $28.01 $967,306 - $1.2 Million
42,669 New
42,669 $1.08 Million
Q1 2022

Mar 22, 2023

BUY
$22.67 - $28.01 $345,830 - $427,292
15,255 Added 55.65%
42,669 $1.08 Million
Q1 2022

May 12, 2022

BUY
$22.67 - $28.01 $345,830 - $427,292
15,255 Added 55.65%
42,669 $1.08 Million
Q4 2021

Jun 21, 2023

SELL
$24.13 - $32.63 $368,103 - $497,770
-15,255 Reduced 35.75%
27,414 $756,000
Q3 2021

Jun 21, 2023

SELL
$29.97 - $36.66 $457,192 - $559,248
-15,255 Reduced 35.75%
27,414 $885,000
Q2 2021

Jun 21, 2023

SELL
$25.39 - $32.61 $387,324 - $497,465
-15,255 Reduced 35.75%
27,414 $838,000
Q1 2021

May 17, 2024

SELL
$19.92 - $31.6 $330,532 - $524,338
-16,593 Reduced 37.71%
27,414 $834,000
Q1 2021

Jun 26, 2023

SELL
$19.92 - $31.6 $303,879 - $482,058
-15,255 Reduced 35.75%
27,414 $835 Million
Q1 2021

Mar 22, 2023

SELL
$19.92 - $31.6 $87,648 - $139,040
-4,400 Reduced 13.83%
27,414 $834,000
Q1 2021

May 14, 2021

SELL
$19.92 - $31.6 $87,648 - $139,040
-4,400 Reduced 13.83%
27,414 $835,000
Q4 2020

Jun 22, 2023

SELL
$12.16 - $19.77 $131,996 - $214,603
-10,855 Reduced 25.44%
31,814 $628,000
Q3 2020

Jun 26, 2023

SELL
$11.25 - $14.75 $122,118 - $160,111
-10,855 Reduced 25.44%
31,814 $414,000
Q2 2020

May 24, 2024

SELL
$10.69 - $16.49 $130,343 - $201,062
-12,193 Reduced 27.71%
31,814 $361 Million
Q2 2020

Jun 26, 2023

SELL
$10.69 - $16.49 $116,039 - $178,998
-10,855 Reduced 25.44%
31,814 $360,000
Q1 2020

Jul 12, 2023

SELL
$9.78 - $29.53 $106,161 - $320,548
-10,855 Reduced 25.44%
31,814 $455,000
Q4 2019

Jul 12, 2023

SELL
$20.93 - $35.1 $227,195 - $381,010
-10,855 Reduced 25.44%
31,814 $866,000
Q3 2019

Jul 12, 2023

SELL
$22.08 - $47.08 $239,678 - $511,053
-10,855 Reduced 25.44%
31,814 $910,000
Q3 2019

Mar 22, 2023

BUY
$22.08 - $47.08 $45,286 - $96,561
2,051 Added 6.89%
31,814 $910,000
Q3 2019

Nov 14, 2019

BUY
$22.08 - $47.08 $45,286 - $96,561
2,051 Added 6.89%
31,814 $911,000
Q2 2019

Jul 12, 2023

SELL
$22.67 - $35.0 $246,082 - $379,925
-10,855 Reduced 25.44%
31,814 $883,000
Q1 2019

Jul 13, 2023

SELL
$26.93 - $34.7 $347,558 - $447,838
-12,906 Reduced 30.25%
29,763 $988,000
Q4 2018

Jul 13, 2023

SELL
$27.23 - $45.56 $351,430 - $587,997
-12,906 Reduced 30.25%
29,763 $865,000
Q4 2018

Mar 22, 2023

SELL
$27.23 - $45.56 $445,755 - $745,817
-16,370 Reduced 35.48%
29,763 $865,000
Q4 2018

Feb 14, 2019

SELL
$27.23 - $45.56 $445,755 - $745,817
-16,370 Reduced 35.48%
29,763 $865,000
Q3 2018

Jul 13, 2023

SELL
$37.57 - $50.34 $484,878 - $649,688
-12,906 Reduced 30.25%
29,763 $1.37 Million
Q3 2018

Mar 22, 2023

BUY
$37.57 - $50.34 $130,142 - $174,377
3,464 Added 8.12%
46,133 $2.12 Million
Q3 2018

Nov 14, 2018

BUY
$37.57 - $50.34 $615,020 - $824,065
16,370 Added 55.0%
46,133 $2.12 Million
Q4 2017

Feb 15, 2018

BUY
$28.45 - $37.14 $846,757 - $1.11 Million
29,763
29,763 $1.02 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.23B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.